← Back to patent-cliff list
CAS 82546-55-2
(2R,4R,5R,7S,10R,14S,15S,16S,18S)-5,7-Dihydroxy-10,14-dimethylspiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolane]-5'-one
Codes：(XVIII)169995-1-b、(VIII)169995-5-a、(V)169995-23-a
Application context (from source-drug indications)
避孕屈螺酮口腔炎，口疮屈螺酮经前焦虑性障碍屈螺酮经前期综合征屈螺酮痛经屈螺酮抑郁屈螺酮
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 屈螺酮Drospirenone | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(1R,2R,4R,5R,10R,11S,14S,15S,16S,18S,19S)-5-Hydroxy-10,14-dimethylspiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolane]-5',7-dione→3-[3beta-[tert-Butyl(dimethyl)silyloxy]-5beta,17beta-dihydroxy-6beta,7beta:15beta,16beta-dimethyleneandrostan-17-yl]-2-propynoic acid ethyl ester→6beta,7beta:15beta,16beta-Dimethylene-3beta-t-butyldimethylsilyloxy-5beta,17beta-dihydroxy-17alpha-(2-ethoxycarbonyl)-ethyl-androstane→(2R,4R,5R,7S,10R,14S,15S,16S,18S)-5,7-Dihydroxy-10,14-dimethylspiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolane]-5'-one
(2S,3'S,5'S,7'S,11'R,14'S)-14'-hydroxy-7',11'-dimethylspiro[oxolane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecan]-16'-en-5-one→(2S,3'S,5'S,7'S,11'R,14'S,18'R)-14',18'-dihydroxy-7',11'-dimethylspiro[oxolane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecan]-16'-en-5-one→(2S,3'S,5'S,7'S,11'R,14'S,18'R)-14'-[(tert-butyldimethylsilyl)oxy]-18'-hydroxy-7',11'-dimethylspiro[oxolane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecan]-16'-en-5-one→(2R,5S,7S,9R,10R,13S,15S,16S,17S)-5-[(tert-butyldimethylsilyl)oxy]-10-hydroxy-2,17-dimethyl-8-oxaspiro[hexacyclo[9.8.0.0(2,7).0(7,9).0(12,17).0(13,15)]nonadecane-16,2'-oxolane]-5'-one→(2R,5S,7S,9S,10S,13S,15S,16S,17S)-5-[(tert-butyldimethylsilyl)oxy]-10-chloro-2,17-dimethyl-8-oxaspiro[hexacyclo[9.8.0.0(2,7).0(7,9).0(12,17).0(13,15)]nonadecane-16,2'-oxolane]-5'-one→(2R,5S,7S,9S,10S,13S,15S,16S,17S)-10-chloro-5-hydroxy-2,17-dimethyl-8-oxaspiro[hexacyclo[9.8.0.0(2,7).0(7,9).0(12,17).0(13,15)]nonadecane-16,2'-oxolane]-5'-one→(2S,3'S,5'S,7'S,11'R,14'S,16'R)-14',16'-dihydroxy-7',11'-dimethylspiro[oxolane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecan]-17'-en-5-one→(2R,4R,5R,7S,10R,14S,15S,16S,18S)-5,7-Dihydroxy-10,14-dimethylspiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolane]-5'-one
(2S,4aR,4bS,6aS,7aS,8aS,8bS,8cR,10aR)-2,10a-Dihydroxy-4a,6a-dimethyl-2,3,4,4a,4b,5,6,6a,7a,8,8a,8b,8c,10a-tetradecahydrocyclopropa[4,5]cyclopenta[1,2-a]phenanthren-7(1H)-one→(1aR,1bR,3S,5aR,5bS,7aS,8aS,9aS,9bS,9cR,9dR)-1b,3-Dihydroxy-5a,7a-dimethylperhydrocyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-one→3-Bromopropionic acid methyl ester→Methyl 3-[(1aR,1bR,3S,5aR,5bS,7aS,8S,8aS,9aS,9bS,9cR,9dR)-1b,3,8-trihydroxy-5a,7a-dimethyloctadecahydro-1H-cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-yl]propanoate→(1aR,1bR,3S,5aR,5bS,7aS,8S,8aS,9aS,9bS,9cR,9dR)-8-(3-Hydroxypropyl)-5a,7a-dimethyloctadecahydro-1bH-cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-1b,3,8-triol→(2R,4R,5R,7S,10R,14S,15S,16S,18S)-5,7-Dihydroxy-10,14-dimethylspiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolane]-5'-one
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.